These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


92 related items for PubMed ID: 28051228

  • 21. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome.
    Kyrieleis HA, Levtchenko EN, Wetzels JF.
    Am J Kidney Dis; 2007 May; 49(5):592-7. PubMed ID: 17472840
    [Abstract] [Full Text] [Related]

  • 22. Outcome Of Short And Long Duration Steroid Therapy In Childhood Nephrotic Syndrome In Terms Of Frequency Of Relapse Rate.
    Jamshaid AA, Akhtar N, Adnan A, Perveen S, Chaudhry A, Fatima T.
    J Ayub Med Coll Abbottabad; 2022 May; 34(2):300-303. PubMed ID: 35576290
    [Abstract] [Full Text] [Related]

  • 23. Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome.
    Vivarelli M, Moscaritolo E, Tsalkidis A, Massella L, Emma F.
    J Pediatr; 2010 Jun; 156(6):965-971. PubMed ID: 20223477
    [Abstract] [Full Text] [Related]

  • 24. [Mycophenolate mofetil (MMF) as the first choice immunosuppressive drug in treatment of steroid-dependent nephrotic syndrome in children].
    Ogarek I, Szczęsny-Choruz E, Wierzchowska-Słowiaczek E, Kwinta-Rybicka J, Stec Z, Moczulska A, Wilkosz K, Drożdż D.
    Pol Merkur Lekarski; 2018 Apr 23; 44(262):192-195. PubMed ID: 29775447
    [Abstract] [Full Text] [Related]

  • 25. Treatment course of steroid-dependent nephrotic syndrome: emphasized on treatment effect.
    Chen SY, Wu CY, Tsai IJ, Tsau YK.
    Nephrology (Carlton); 2010 Apr 23; 15(3):336-9. PubMed ID: 20470303
    [Abstract] [Full Text] [Related]

  • 26. Mycophenolate mofetil in treatment of childhood steroid-dependent nephrotic syndrome.
    Jellouli M, Fitouhi S, Abidi K, Hammi Y, Naija O, Zarrouk C, Gargah T.
    Tunis Med; 2016 Mar 23; 94(3):221-5. PubMed ID: 27575507
    [Abstract] [Full Text] [Related]

  • 27. Spontaneous remissions in frequently relapsing and steroid dependent idiopathic nephrotic syndrome.
    Wingen AM, Müller-Wiefel DE, Schärer K.
    Clin Nephrol; 1985 Jan 23; 23(1):35-40. PubMed ID: 3978880
    [Abstract] [Full Text] [Related]

  • 28. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
    Huang J, Du J, Wang S, Xiao L, Zhao X.
    Zhonghua Er Ke Za Zhi; 2014 Jul 23; 52(7):521-4. PubMed ID: 25224058
    [Abstract] [Full Text] [Related]

  • 29. Clinical outcomes in children with Henoch-Schönlein purpura nephritis without crescents.
    Delbet JD, Hogan J, Aoun B, Stoica I, Salomon R, Decramer S, Brocheriou I, Deschênes G, Ulinski T.
    Pediatr Nephrol; 2017 Jul 23; 32(7):1193-1199. PubMed ID: 28204946
    [Abstract] [Full Text] [Related]

  • 30. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.
    Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, Dötsch J.
    Nephrol Dial Transplant; 2012 May 23; 27(5):1910-5. PubMed ID: 22076431
    [Abstract] [Full Text] [Related]

  • 31. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.
    Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D.
    Pediatr Nephrol; 2016 Apr 23; 31(4):589-94. PubMed ID: 26525199
    [Abstract] [Full Text] [Related]

  • 32. [The treatment with levamisole of frequently recurring steroid-sensitive idiopathic nephrotic syndrome in children].
    Kemper MJ, Amon O, Timmermann K, Altrogge H, Müller-Wiefel DE.
    Dtsch Med Wochenschr; 1998 Feb 27; 123(9):239-43. PubMed ID: 9524533
    [Abstract] [Full Text] [Related]

  • 33. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
    Ravani P, Bonanni A, Rossi R, Caridi G, Ghiggeri GM.
    Clin J Am Soc Nephrol; 2016 Apr 07; 11(4):710-20. PubMed ID: 26585985
    [Abstract] [Full Text] [Related]

  • 34. Predictors of relapse in steroid-sensitive nephrotic syndrome.
    Noer MS.
    Southeast Asian J Trop Med Public Health; 2005 Sep 07; 36(5):1313-20. PubMed ID: 16438164
    [Abstract] [Full Text] [Related]

  • 35. Does cyclosporine achieve a real advantage for treatment of idiopathic nephrotic syndrome in children? A long-term efficacy and safety study.
    Sheashaa H, Mahmoud I, El-Basuony F, El-Husseini A, Hassan N, El-Baz M, Ahmed NS, Sobh M.
    Int Urol Nephrol; 2007 Sep 07; 39(3):923-8. PubMed ID: 17447154
    [Abstract] [Full Text] [Related]

  • 36. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated.
    Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J.
    Nephrol Dial Transplant; 2007 Aug 07; 22(8):2183-93. PubMed ID: 17504846
    [Abstract] [Full Text] [Related]

  • 37. Plasma levels of oxidative stress in children with steroid-sensitive nephrotic syndrome and their predictive value for relapse frequency.
    Fan A, Jiang X, Mo Y, Tan H, Jiang M, Li J.
    Pediatr Nephrol; 2016 Jan 07; 31(1):83-8. PubMed ID: 26341250
    [Abstract] [Full Text] [Related]

  • 38. High incidence of initial and late steroid resistance in childhood nephrotic syndrome.
    Kim JS, Bellew CA, Silverstein DM, Aviles DH, Boineau FG, Vehaskari VM.
    Kidney Int; 2005 Sep 07; 68(3):1275-81. PubMed ID: 16105061
    [Abstract] [Full Text] [Related]

  • 39. Relationship between time to clinical remission and relapse in adults with steroid-sensitive minimal change disease: a retrospective cohort study.
    Ye X, Gao S, Shen K, Xiao Z, Liu H, Pan Q, Xu Y.
    Ann Med; 2024 Dec 07; 56(1):2409344. PubMed ID: 39387505
    [Abstract] [Full Text] [Related]

  • 40. Effect of levamisole in steroid-dependent nephrotic syndrome.
    Madani A, Isfahani ST, Rahimzadeh N, Fereshtehnejad SM, Hoseini R, Moghtaderi M, Mohseni P, Ataiee N.
    Iran J Kidney Dis; 2010 Oct 07; 4(4):292-6. PubMed ID: 20852369
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 5.